Aclarion, Inc. (Nasdaq: ACON, ACONW) today announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial, marking the first private practice site to join the study. Based in Beverly Hills, Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of advanced technologies, and high surgical volume. This inclusion reflects a growing interest in integrating Aclarion's Nociscan technology into real-world clinical workflows beyond academic medical centers.
The CLARITY trial is a prospective, randomized, multi-center study evaluating Nociscan in patients undergoing surgical treatment (fusion or total disc replacement) for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints collected. The company anticipates an initial internal data readout and expected public disclosure of early interim results in Q4 2026. The addition of a high-volume private practice site is expected to accelerate enrollment in the 300-patient study.
Dr. Todd Lanman, founder of Lanman Spinal Neurosurgery and a neurosurgeon with over 25 years of experience, emphasized the significance of the trial. “We have made significant progress in moving beyond one-size-fits-all solutions for low back pain, driven by advances in technology and technique,” said Lanman. “Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs. This ability to match the right procedure to the right patient is what moves the field forward.”
Chronic low back pain affects an estimated 266 million people worldwide, representing a global healthcare challenge. Aclarion's Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology uses magnetic resonance spectroscopy (MRS) data from an MRI machine, which is processed in the cloud using proprietary signal processing techniques to extract and quantify chemical biomarkers associated with disc pain. Biomarker data is then entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and has demonstrated a 97% surgical success rate when all Nociscan-positive discs are treated.
Ryan Bond, Chief Strategy Officer of Aclarion, highlighted the importance of private practice involvement. “Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice,” said Bond. “Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care, and we are excited to partner with his team as we continue to expand CLARITY and generate the high-quality evidence needed to advance Nociscan.”
For more information about the CLARITY trial, visit CLARITY Trial. To find a Nociscan center, view the site map here.
